Ion Beam Applications (OTCMKTS:IOBCF) and Biotricity (OTCMKTS:BTCY) Head-To-Head Contrast

Ion Beam Applications (OTCMKTS:IOBCF) and Biotricity (OTCMKTS:BTCY) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Profitability

This table compares Ion Beam Applications and Biotricity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ion Beam Applications	N/A	N/A	N/A
Biotricity	-163.11%	N/A	-252.90%

Institutional & Insider Ownership

14.9% of Ion Beam Applications shares are owned by institutional investors. Comparatively, 32.5% of Biotricity shares are owned by institutional investors. 20.5% of Biotricity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Ion Beam Applications and Biotricity’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ion Beam Applications	N/A	N/A	N/A	$0.08	112.31
Biotricity	$10.60 million	0.88	-$18.66 million	($1.69)	-0.64

Ion Beam Applications has higher earnings, but lower revenue than Biotricity. Biotricity is trading at a lower price-to-earnings ratio than Ion Beam Applications, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Ion Beam Applications and Biotricity, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ion Beam Applications	0	0	0	0	N/A
Biotricity	0	0	1	0	3.00

Biotricity has a consensus price target of $12.00, indicating a potential upside of 1,000.92%. Given Biotricity’s higher possible upside, analysts clearly believe Biotricity is more favorable than Ion Beam Applications.

Summary

Biotricity beats Ion Beam Applications on 5 of the 9 factors compared between the two stocks.

About Ion Beam Applications

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.